<?xml version="1.0" encoding="UTF-8"?>
<p>Taking into account the difficulties related to the clinical use of ABC transporter inhibitors, the design of prodrugs able to elude the transporters would appear to be a promising solution to this problem. Moreover, new formulations able to target the drugs in the CNS bypassing the BBB are emerging. The loading of ABC transporter inhibitors in this last type of formulation could open interesting perspectives for the selective target of their action within the central nervous system [
 <xref rid="B28-pharmaceutics-10-00039" ref-type="bibr">28</xref>].
</p>
